Zydus Lifesciences has expanded its companion diagnostics portfolio with the launch of Diasens™ and GlucoLive™, an AI-powered Continuous Glucose Monitoring (CGM) system. This next-generation device targets patients with diabetes, Chronic Kidney Disease (CKD), and post-transplant needs. It offers automatic, real-time glucose streaming and integrates with the GoodFlip™ app, providing AI analytics and remote care capabilities in partnership with TatvaCare™.
Zydus Unveils Advanced CGM Technology
Zydus Lifesciences Limited announced on March 12, 2026, the launch of its new companion diagnostics offering: Diasens™ and GlucoLive™. These devices represent a next-generation Continuous Glucose Monitoring (CGM) system incorporating artificial intelligence-powered insights and integrated remote care functionalities.
The new CGM system is specifically designed for patients managing chronic conditions, including diabetes, Chronic Kidney Disease (CKD), and those who have undergone organ transplants, all of whom require continuous glycaemic surveillance.
Key Features and AI Integration
A major differentiator is the system’s ability to stream glucose readings automatically to a smartphone every three minutes, eliminating the need for manual scanning common with existing devices. This ensures uninterrupted capture, even overnight or during emergencies.
The system integrates with the GoodFlip™ app, designed by Zydus’s partner, Digicare Health Solutions Private Limited (TatvaCare™). This platform uses AI analytics to:
- Detect trends and flag hypo-/hyperglycaemic episodes.
- Link glucose fluctuations to food and activity.
- Generate actionable insights.
Furthermore, a dedicated clinician dashboard supports remote monitoring, enabling early intervention and data-driven treatment adjustments for healthcare providers.
Partnership for Integrated Care Ecosystem
The partnership with TatvaCare™ leverages its proprietary integrated care ecosystem, GoodFlip™, to offer a comprehensive suite of services directly through the mobile application. These services include AI-powered report analysis, personalized diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault.
Addressing India’s Disease Burden
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, highlighted the critical need for this technology, noting that India is home to over 101 million adults living with diabetes. The announcement also underscored that diabetes is the leading cause of CKD in India, with approximately 25-40% of CKD patients having a diabetes history. The solution aims to offer a quick, reliable, and safe glucose monitoring solution with utmost convenience for these high-risk populations.
About the Companies
Zydus Lifesciences Limited
Zydus is described as an innovation-led global life sciences company focused on discovering, developing, manufacturing, and marketing a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R&D.
Digicare Health Solutions Private Limited (TatvaCare™)
TatvaCare™ is identified as a healthcare technology company focused on advancing care delivery through digital innovation. Their portfolio includes EMR platforms, conversational knowledge platforms, and digital therapeutics applications like GoodFlip™, supporting conditions such as diabetes, COPD, and asthma.
Source: BSE
